Open AccessIs concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients?
Author(s) -
Vincenzo De Francesco,
Angelo Zullo,
Cesare Hassan
Publication year - 2012
Publication title -
world journal of gastrointestinal pharmacology and therapeutics
Language(s) - English
Resource type - Journals
ISSN - 2150-5349
DOI - 10.4292/wjgpt.v3.i6.103
Subject(s) - lansoprazole , clarithromycin , concomitant , metronidazole , amoxicillin , medicine , helicobacter pylori , gastroenterology , pharmacotherapy , surgery , antibiotics , microbiology and biotechnology , biology
The study found that the 7 d of concomitant therapy (lansoprazole, amoxicillin, clarithromycin and metronidazole) achieved significantly higher eradication rates compared to 7 d of triple therapy (lansoprazole, amoxicillin, clarithromycin), the intention to treat (ITT) cure rates being 94.9% and 68.3%, respectively. According to our opinion, this study is clinically relevant for Japanese physicians for at least 2 reasons: (1) the standard triple therapy (clarithromycin plus amoxicillin) achieved disappointing cure rates in Japan - in agreement with what was observed in several countries; and (2) the concomitant quadruple therapy is an effective therapeutic alternative.